ArticleInternal and emergency medicine2026
Altered cholangiocyte subsets with neural pathway enrichment in metabolic dysfunction-associated steatotic liver disease.
Article in Internal and emergency medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocytes have been extensively studied in metabolic dysfunction-associated steatotic liver disease (MASLD), yet the role of cholangiocytes remains underexplored. We utilized a comprehensive approach that integrates high-dimensional weighted gene co-expression network analysis (hdWGCNA), cellular interaction evaluation, machine learning techniques, immune cell infiltration analysis, and Mendelian randomization to investigate both single-cell sequencing data and bulk sequencing datasets. Single-cell analysis identified significant alterations in cholangiocyte subpopulations in metabolic dysfunction-associated steatohepatitis (MASH) patients, including an increase in cholangiocytes with elevated SEMA3 pathway expression. The hdWGCNA analysis identified the green module, which is enriched with genes associated with neural pathways pertinent to MASH. Seven machine learning models assessed the diagnostic feasibility of key genes in the green module for MASLD spectrum. Immune infiltration analysis highlighted complex interactions between cholangiocytes enriched for neural-related pathways and immune cells, particularly neutrophils and monocytes. Patient stratification identified two distinct subtypes within the MASLD spectrum, with subtype 2 exhibiting enhanced activity in neural-related pathways. Mendelian randomization analysis identified PLEKHA5 as a candidate causal gene for MASLD, suggesting a potential role in neural mechanisms (SEL1L3 showed a suggestive association, P = 0.0413). Collectively, this hypothesis-generating bioinformatics study elucidates distinct characteristics of cholangiocyte subpopulations in MASH, revealing neural pathway alterations that may contribute to disease pathogenesis and providing a foundation for future investigation into cholangiocyte-related mechanisms in MASLD.
Indexed as
Identifiers
42879090What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.